A Kisser1, I Zechmeister-Koss. 1. Ludwig Boltzmann Institute for Health Technology Assessment, Vienna, Austria.
Abstract
BACKGROUND: Screening for cervical cancer precursors by Papanicolaou cytology is a public health success story; however, its low sensitivity entails unnecessary referrals to colposcopy of healthy women with equivocal (ASCUS) or mild dysplasia (LSIL) cytology. OBJECTIVE: We assessed the accuracy of p16/Ki-67 immuno-testing for triage of low grade cervical cytology. SEARCH STRATEGY: We systematically searched Medline, Embase, CRD and Cochrane databases, and handsearched key references. SELECTION CRITERIA: Eligible studies included women with ASCUS or LSIL cervical cytology who had undergone p16/Ki-67 testing and subsequent verification by colposcopy-directed biopsies and histologic analysis. DATA COLLECTION AND ANALYSIS: We extracted data on patient characteristics and test conduct, diagnostic accuracy measures and assessed the methodological quality of the studies. R software was used to perform a bivariate analysis of test performance data. MAIN RESULTS: Five eligible studies were identified. Four of the studies had high risk of bias. In the LSIL subgroup, the sensitivity of p16/Ki-67 testing ranged from 0.86 to 0.98, compared with 0.92-0.96 of high-risk HPV testing (hrHPV); specificity ranged from 0.43 to 0.68 versus 0.19 to 0.37, respectively. In the ASCUS subgroup, sensitivity ranged from 0.64 to 0.92 (p16/Ki67 test) versus 0.91 to 0.97 (hrHPV); specificity ranged from 0.53 to 0.81 versus 0.26 to 0.44, respectively. AUTHORS' CONCLUSIONS: p16/Ki-67 testing cannot be recommended for triage women with ASCUS or LSIL cytology due to insufficient high-quality evidence. Further studies on test performance and the impact of p16/Ki-67-based triage on health outcomes are needed for a definitive evaluation of its clinical utility.
BACKGROUND: Screening for cervical cancer precursors by Papanicolaou cytology is a public health success story; however, its low sensitivity entails unnecessary referrals to colposcopy of healthy women with equivocal (ASCUS) or mild dysplasia (LSIL) cytology. OBJECTIVE: We assessed the accuracy of p16/Ki-67 immuno-testing for triage of low grade cervical cytology. SEARCH STRATEGY: We systematically searched Medline, Embase, CRD and Cochrane databases, and handsearched key references. SELECTION CRITERIA: Eligible studies included women with ASCUS or LSIL cervical cytology who had undergone p16/Ki-67 testing and subsequent verification by colposcopy-directed biopsies and histologic analysis. DATA COLLECTION AND ANALYSIS: We extracted data on patient characteristics and test conduct, diagnostic accuracy measures and assessed the methodological quality of the studies. R software was used to perform a bivariate analysis of test performance data. MAIN RESULTS: Five eligible studies were identified. Four of the studies had high risk of bias. In the LSIL subgroup, the sensitivity of p16/Ki-67 testing ranged from 0.86 to 0.98, compared with 0.92-0.96 of high-risk HPV testing (hrHPV); specificity ranged from 0.43 to 0.68 versus 0.19 to 0.37, respectively. In the ASCUS subgroup, sensitivity ranged from 0.64 to 0.92 (p16/Ki67 test) versus 0.91 to 0.97 (hrHPV); specificity ranged from 0.53 to 0.81 versus 0.26 to 0.44, respectively. AUTHORS' CONCLUSIONS:p16/Ki-67 testing cannot be recommended for triage women with ASCUS or LSIL cytology due to insufficient high-quality evidence. Further studies on test performance and the impact of p16/Ki-67-based triage on health outcomes are needed for a definitive evaluation of its clinical utility.
Authors: Roosmarijn Luttmer; Maaike G Dijkstra; Peter J F Snijders; Johannes Berkhof; Folkert J van Kemenade; Lawrence Rozendaal; Theo J M Helmerhorst; René H M Verheijen; W Abraham Ter Harmsel; W Marchien van Baal; Peppino G C M Graziosi; Wim G V Quint; Johan W M Spruijt; Dorenda K E van Dijken; Daniëlle A M Heideman; Chris J L M Meijer Journal: Mod Pathol Date: 2016-05-06 Impact factor: 7.842
Authors: Júlio C Possati-Resende; José H T G Fregnani; Ligia M Kerr; Edmundo C Mauad; Adhemar Longatto-Filho; Cristovam Scapulatempo-Neto Journal: PLoS One Date: 2015-07-31 Impact factor: 3.240